However, with the introduction and clinical availability of infliximab (Knight et al., 1993; van Dullemen et al., 1995), the first tumor necrosis factor α (TNFα) antagonist for the treatment of CD, problems with its efficacy emerged. Here, TNF is linked to Cowden disease.